Страна: Канада
Язык: английский
Источник: Health Canada
IOTHALAMATE MEGLUMINE
LIEBEL-FLARSHEIM COMPANY LLC
V08AA04
IOTALAMIC ACID
600MG
SOLUTION
IOTHALAMATE MEGLUMINE 600MG
INTRAVASCULAR
30
Ethical
ROENTGENOGRAPHY
Active ingredient group (AIG) number: 0102763001; AHFS:
APPROVED
2002-07-02
_Product Monograph _ _ _ _Прочитать полный документ _ _Page 1 of 32_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION CONRAY ® 60 Iothalamate meglumine injection Solution, 60% w/v, Intravascular USP Ionic Iodinated Radiographic Contrast Medium for Intravascular Use DIN Holder: Liebel-Flarsheim Company LLC 8800 Durant Road Raleigh, NC 27616 USA Importer: Liebel-Flarsheim Canada Inc. 7500 Trans-Canada Highway Pointe-Claire, QC, H9R 5H8 CANADA Date of Initial Authorization: DEC 31, 1951 Date of Revision: AUG 23, 2022 Submission Control Number: 261648 _ _ _Product Monograph _ _ _ _ < Iothalamate meglumine injection> _ _Page 2 of 32_ RECENT MAJOR LABEL CHANGES Not applicable TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 5 1 INDICATIONS .............................................................................................................. 5 1.1 Pediatrics .......................................................................................................... 5 1.2 Geriatrics........................................................................................................... 5 2 CONTRAINDICATIONS ................................................................................................. 5 4 DOSAGE AND ADMINISTRATION................................................................................. 6 4.1 Dosing Considerations ....................................................................................... 6 4.2 Recommended Dose and Dosage Adjustment..................................................... 6 4.2.1 Arthrography ..............